Relief in sight for restless legs syndrome.
Rye
David B
DB
D000077465:Cabergoline; D018450:Disease Progression; D018491:Dopamine Agonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004873:Ergolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease; D006801:Humans; D012148:Restless Legs Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D016896:Treatment Outcome
D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline